



Kenneth J. Van Heel

Global Director of Corporate Strategic Planning and Ventures & Business Development

The Dow Chemical Company

Kenneth J. Van Heel is Global Director of Corporate Strategic Planning and Ventures & Business Development, The Dow Chemical Company. Ken assumed the responsibility for Ventures & Business Development in 2018. In 2016 he was named Global Director of Corporate Strategic Planning and manages a team with responsibilities including annual and long term planning, capital project analysis and planning, joint venture governance, and strategic evaluation working closely with Corporate Strategy and senior management.

Prior to this Ken was Global Director of Alternative Investments and CIO of the Dow Chemical Canada Pension Plan for Portfolio Investments. From 2007, Ken led a team of investment professionals managing global investment strategy, execution and monitoring of investments in private equity investments, real estate, and real assets and infrastructure for pension plan and insurance assets at Dow. Ken assumed CIO responsibilities for the Dow Canada pension plans in 2013 managing the plans' investments. From mid-2008 through 2009 Ken also had responsibility as Global Director of Dow's Corporate Venture Capital. Before joining Portfolio Investments as a Sr. Investment Manager in 2003, Ken was an investment manager in the Corporate Venture Capital group at Dow. Ken joined Dow in 1986 and held sales and marketing positions before assuming commercial business development roles starting in 1994 in Ventures and New Business (Advanced Materials and Electronics), as well as Performance Chemicals.

Ken has a broad external network across private markets and his transaction experience includes private equity and venture capital investments, spin-outs, divestitures, and strategic partnerships. Ken serves on the investment committee for the Midland Center for the Arts, and is a board member for WaterHealth International Inc. and Gantec Inc. He previously served on the board of Pfenex Inc. (NYSE: PFNX) through its IPO, and Cytopherx Inc. Ken has a B.S. in Materials Science from Illinois Institute of Technology and a M.B.A. in Finance from DePaul University.